A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)
Withdrawn
Schering-Plough
Phase 2
2003-04-01
The purpose of this research study is to obtain experience in the use of fondaparinux
(Arixtra) as compared to heparin when administered to patients who undergo percutaneous
coronary intervention (PCI). PCI is a mechanical procedure used to widen the narrowing in a
coronary artery in patients with symptomatic coronary artery disease. Fondaparinux and
heparin are drugs that inhibit blood clotting.
Fondaparinux as an Anticoagulant in Haemofiltration in Patients With Acute Kidney Failure.
Terminated
Melbourne Health
N/A
2004-06-01
The purpose of this project is to assess the safety and effectiveness of fondaparinux, a new
drug to prevent blood clotting in the continuous dialysis machine used in intensive care
patients who have kidney failure.
This is a local registration study in China to compare the safety and efficacy of ARIXTRA to
Enoxaparine in patients undergoing elective major hip or knee replacement or a revision of
components.
Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis
Completed
Children's Hospital Los Angeles
Phase 1
2006-09-01
This study will evaluate the use of a blood thinner, fondaparinux, which is approved for use
in adults (not in children) in a children aged 1-18 years. Subject with a blood clot
(thrombosis) or heparin-induced thrombocytopenia who need to be on a blood thinner will be
eligible to participate. Subjects will receive a once daily dose of fondaparinux followed by
blood tests at 2, 4, 12, and 24 hours after the first dose in order to determine the proper
dose for this age group. The hypothesis is that children receiving fondaparinux will be able
to receive a once daily dose. The currently available alternative agent, enoxaparin, needs to
be given twice daily. In addition, an evaluation of the safety of this medication will be
made by assessing for side effects, especially bleeding.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
